Current Perspective: The Role of Liquid Biopsy in Diagnosis and Management of Pediatric Rhabdomyosarcomas (RMS)
Liquid biopsy offers hope for less invasive diagnosis and monitoring in childhood rhabdomyosarcoma, where tissue sampling is difficult and real-time tracking is crucial.
This current perspective synthesises liquid biopsy approaches (ctDNA, miRNA, EVs, CTC) in paediatric rhabdomyosarcoma, a rare and aggressive cancer with dismal metastatic prognosis and limited biomarker options. The field is early-stage with small patient series, but liquid biopsy could enable less invasive diagnosis and real-time monitoring in a population where tissue biopsies are challenging.
What the study was
- Study design
- narrative_review
- Category
- early_cancer_detection_liquid_biopsy
- Maturity
- Exploratory
- Journal
- Pediatric Hematology and Oncology
Why it surfaced
Paediatric RMS is a high-unmet-need rare cancer; liquid biopsy in RMS is early-stage and review-level. Score 4 (N=1, D=1, P=2, E=0) reflecting high disease urgency but absence of new data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.